Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738,…
$SMMT A long shot PDUFA for (IMHO) an active drug developed (in the case of the FDA submission) in a high-risk trial structure. No OS in 1’ endpoint. FDA only accepting OS is known. Next we get a look at Harmoni3, a better designed study to demonstrate OS. Ivonescimab IMHO hits…
17 analysts rate SMMT Buy on consensus.
Consensus price target: $29.77 (+199.2% upside from $9.95)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| DUGGAN ROBERT W director, 10 percent owner, Co-Chief Executive Officer | Jun 12, 2026 | Purchase | 3,810,000 | $49.99M |
| Zanganeh Mahkam director, 10 percent owner, Co-Chief Executive Officer | Jun 12, 2026 | Purchase | 3,810,000 | $49.99M |
| Soni Manmeet Singh director, COO and CFO | Jun 4, 2026 | Purchase | 25,000 | $361.5K |
| Soni Manmeet Singh director, COO and CFO | Jun 4, 2026 | Purchase | 25,000 | $360.75K |
| Zanganeh Mahkam director, 10 percent owner, Co-Chief Executive Officer | Jun 4, 2026 | Purchase | 100,000 | $1.46M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-1.08B |
| 2024 | $0 | — | $-176.77M |
| 2023 | $0 | -100% | $-482.37M |
Stock data for SMMT: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics